Scapa Group plc provided earnings guidance for the year 2020. The company expected financial year 2020 revenue to be approximately £306 million, broadly in line with market expectations. However, trading profit is now expected to be approximately £28 million, significantly below consensus. Healthcare revenue is estimated to be approximately £139 million, slightly ahead of market expectations and greater than last year despite the loss of the ConvaTec contract. Healthcare trading profit is expected to be lower than consensus, reflecting slower progress in reducing costs than expected at the time of the interim results. The Group continues to focus on pipeline of new programs as leverage technologies and capabilities to drive organic growth and reduce the cost of operations.